Hester Biosciences announced a strong first-quarter performance for FY26. The company reported over 131% growth in consolidated net profit and a positive turnaround in its African subsidiary.
Hester Biosciences reported a consolidated net profit of ₹17.30 crore for Q1FY26, marking a 131% increase compared to ₹7.49 crore in the same period last year. This strong growth was primarily supported by cost optimisation and a significant recovery in operations at Hester Africa, which returned to profitability during the quarter.
The company’s consolidated revenue from operations stood at ₹84.11 crore, showing a 2% year-on-year rise. Gross profit margins remained stable due to an optimal product mix, while improved absorption of fixed costs contributed to a rise in both EBITDA and PAT margins.
Hester Africa delivered a net profit of ₹5.50 crore in Q1FY26, reversing a loss of ₹5 crore from the previous year. The topline improved significantly to ₹17.23 crore from ₹2.80 crore, marking a 516% growth. This turnaround was attributed to enhanced commercial execution, improved market penetration, and a stabilised manufacturing base in Tanzania.
With expanding demand across the African continent, the company aims to scale its international operations further and continue its growth momentum.
Hester Nepal, another subsidiary, posted a net profit of ₹1.92 crore in Q1FY26, slightly lower than ₹2.73 crore in the previous year. Revenue declined to ₹5.08 crore from ₹6.32 crore. Despite this, the unit continued to meet institutional orders and retained its operational strength in the region.
Standalone revenues came under pressure, declining 14% to ₹63.49 crore in Q1FY26 from ₹73.47 crore in Q1FY25. The Animal Healthcare division experienced a 33% dip in sales due to delays in government immunisation programmes for PPR and Lumpy Skin Disease. These programmes, which use Hester’s vaccines, are expected to commence in the upcoming quarters.
Nonetheless, the division introduced alternative products and maintained steady demand for therapeutic offerings to address earlier regulatory constraints.
The Poultry Healthcare division registered a 2% rise in revenue, supported by strong demand for key vaccines including Newcastle Disease and Marek’s Disease. The division also expanded its feed supplements and disinfectant range, which are gaining traction and are expected to contribute more robustly in future quarters.
Technical support initiatives and customer partnerships were further strengthened to maintain competitive positioning.
Read More: Weekly Market Recap: What Happened in the Week of July 28 – August 1, 2025?
Hester Biosciences share price ended higher by over 12% on August 1, 2025.
Hester Biosciences has undertaken several structural reforms in sales, marketing, and research and development to enhance future performance. These changes are anticipated to yield tangible results in the forthcoming quarters. Key areas of focus for the company include: Launch of its Avian Influenza vaccine, Strengthening the feed supplement and disinfectant portfolio, Diversification in the Animal Healthcare segment and Scaling international operations, particularly in Africa
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Aug 1, 2025, 4:43 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
